

07:30 Registration & Coffee

08:20 Opening Speech by Leonard Sachs, Managing Director, Sachs Associates Ltd.

08:30 Deal Making
 Co-Chaired by:
 Anne Altmeyer, VP Business Development Negotiations, Baxalta
 Beth Jacobs, Managing Partner, Excellentia Global Partners
 Panellists:
 Jeff Bockman, Vice President, Defined Health
 Jeffrey Bacha, Chairman and Chief Executive Officer, DelMar Pharmaceuticals, Inc.
 Michael Woo, Director, Search & Evaluation ImmunoOncology, External Innovation, Global Research & Development, EMD Serono, Inc.
 Mohamed Ragab, VP Oncology, S&E, BD, Bristol-Myers Squibb Company
 Niels Emmerich, Senior Director, Head Search and Evaluation, Oncology, AbbVie, Inc.
 Peter Hoang, Senior Vice President, Business Development & Strategy, Bellicum Pharmaceuticals, Inc.

09:20 Public Markets & Finance
 Chaired by:
 Matthew Roden, UBS Equity Research, UBS
 Panellists:
 Daniel Teper, CEO, Immune Pharmaceuticals, Inc.
 Joseph Brantuk, Vice President, Global Corporate Client Group, Nasdaq OMX
 Michael Aberman, SVP, Strategy and Investor Relations, Regeneron Pharmaceuticals, Inc.
 Peter Kolchinsky, Managing Director, RA Capital Management
 Stuart Barich, Managing Director, Raymond James Financial, Inc.

10:05 Coffee Break

10:20 IO Combination Strategies
 Co-Chaired by:
 James Mulé, Associate Center Director for Translational Research, Moffitt Cancer Center
 Paul Rennert, Founder & Principal, SugarCone Biotech, LLC
 Panellists:
 Maurice Zauderer, Founder, President & CEO, Vaccinex, Inc.
 Michael Khan, Chief Medical Officer, Silence Therapeutics
 Niranjana Sardesai, COO, Inovio Pharmaceuticals, Inc.
 Robert Petit, EVP CSO, Advaxis, Inc.
 Steve Worland, President & Chief Executive Officer, eFFECTOR Therapeutics, Inc.
 Thomas Davis, Executive Vice President, CMO, Celldex Therapeutics

Presenting Track A
 Moderated by: Maxim Jacobs, Edison Investment Research

10:20 Karus Therapeutics Ltd.

10:40 Abzena PLC - [LON:ABZA]

11:20 Keynote Speech "Genetic reprogramming of T cells for human applications"
 by Laurence Cooper, CEO, ZIOPHARM Oncology, Inc.
 Visiting Scientist, Pediatrics – Research, MD Anderson Cancer Center

11:00 ISA Pharmaceuticals B.V.

11:50 Cell & Gene Therapy
 Chaired by:
 Boris Peaker, Managing Director, Biotechnology Equity Research, Cowen Group
 Panellists:
 André Choulrika, Chairman and CEO, Collectis
 Laurence Cooper, CEO, ZIOPHARM Oncology, Inc.
 and Visiting Scientist, Pediatrics – Research, MD Anderson Cancer Center
 Pedro Lichtinger, Chief Executive Officer, Asterias Biotherapeutics, Inc.
 Stephen Rubino, Global Head, Business Development and
 New Products Marketing, Cell & Gene Therapy Unit, Novartis Pharmaceutical Corporation
 Tom Farrell, CEO, Bellicum Pharmaceuticals, Inc.

11:10 Available

11:20 Mirna Therapeutics, Inc. - [NASDAQ:MIRN]

11:40 Advaxis, Inc. - [NASDAQ:ADXS]

12:00 Inovio Pharmaceuticals, Inc. - [NASDAQ:INO]

12:40 Networking Lunch

Presenting Track B
Moderated by: Paul Rennert, SugarCone Biotech, LLC

Presenting Track C
Moderated by: Sherry Grisewood, Dawson James Securities, Inc.

13:40 Silence Therapeutics - [LON:SLN]

13:40 Asterias Biotherapeutics, Inc. - [NYSEMKT:AST]

14:00 Immune Pharmaceuticals, Inc. - [NASDAQ:IMNP]

14:00 DelMar Pharmaceuticals, Inc. - [OTCMKTS:DMPI]

14:20 Bellicum Pharmaceuticals, Inc. - [NASDAQ:BLCM]

14:20 Aethlon Medical, Inc. - [NASDAQ:AEMD]

14:40 Vaccinex, Inc.

14:40 OncoSec Medical, Inc. - [NASDAQ:ONCS]

15:00 F-star Biotechnology Limited

15:00 XBiotech USA, Inc. - [NASDAQ:XBIT]

15:20 eFFECTOR Therapeutics, Inc.

15:20 BeyondSpring Pharmaceuticals, Inc.

15:40 Coffee Break

16:00 **Early Stage Investment**
Chaired by:
Steve Dickman , Chief Executive Officer, CBT Advisors
Panellists:
Bibhash Mukhopadhyay, Principal, New Enterprise Associates
Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center
Howard Fingert, Senior Medical Director, Internal and External Innovation
for Oncology, Takeda Pharmaceuticals
Laurent Audoly, Managing Partner - Head of R&D, Pierre Fabre Fund For Innovation
Robert Urban, Head of the Johnson & Johnson Innovation, Boston
William Kuziel, Director, External Scientific Affairs, Daiichi Sankyo Group

16:45 **Late Stage Investment**
Chaired by:
Steve Dickman , Chief Executive Officer, CBT Advisors
Panellists:
Bard Geesaman, Managing Director, MPM Capital
Brad Loncar, Chief Executive Officer, Loncar Investments, LLC
Chris Marai, Managing Director, Biotechnology Equity Research, Oppenheimer & Co. Inc.
Dennis Purcell, Founder and Senior Advisor, Aisling Capital, LLC

17:30 Networking Reception

18:30 End of the 4th CBPI Forum

Silver Sponsor:



Supported by:



NOTES:
